1 - 25 of 82 results for author:"Holtzman D.M." in Literature citations
Results Customize
| Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. Hashimoto T., Serrano-Pozo A., Hori Y., Adams K.W., Takeda S., Banerji A.O., Mitani A., Joyner D., Thyssen D.H., Bacskai B.J. et al. J. Neurosci. 32:15181-15192(2012) · Mapped (5) |
| Bcl-x pre-mRNA splicing regulates brain injury after neonatal hypoxia-ischemia. Xiao Q., Ford A.L., Xu J., Yan P., Lee K.Y., Gonzales E., West T., Holtzman D.M., Lee J.M. J. Neurosci. 32:13587-13596(2012) · Mapped (5) |
| Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Abeta clearance in a mouse model of beta-amyloidosis. Castellano J.M., Deane R., Gottesdiener A.J., Verghese P.B., Stewart F.R., West T., Paoletti A.C., Kasper T.R., DeMattos R.B., Zlokovic B.V. et al. Proc. Natl. Acad. Sci. U.S.A. 109:15502-15507(2012) · Mapped (16) |
| Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. Hunter J.M., Cirrito J.R., Restivo J.L., Kinley R.D., Sullivan P.M., Holtzman D.M., Koger D., Delong C., Lin S., Zhao L. et al. Brain Res. 1467:120-132(2012) · Mapped (13) |
| In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. Wildsmith K.R., Basak J.M., Patterson B.W., Pyatkivskyy Y., Kim J., Yarasheski K.E., Wang J.X., Mawuenyega K.G., Jiang H., Parsadanian M. et al. PLoS ONE 7:e38013-e38013(2012) · Mapped (18) |
| Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Koffie R.M., Hashimoto T., Tai H.C., Kay K.R., Serrano-Pozo A., Joyner D., Hou S., Kopeikina K.J., Frosch M.P., Lee V.M. et al. Brain 135:2155-2168(2012) · Mapped (5) |
| Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Bell R.D., Winkler E.A., Singh I., Sagare A.P., Deane R., Wu Z., Holtzman D.M., Betsholtz C., Armulik A., Sallstrom J. et al. Nature 485:512-516(2012) · Mapped (13) |
| Trans-cellular propagation of Tau aggregation by fibrillar species. Kfoury N., Holmes B.B., Jiang H., Holtzman D.M., Diamond M.I. J. Biol. Chem. 287:19440-19451(2012) · Mapped (6) |
| Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. Basak J.M., Verghese P.B., Yoon H., Kim J., Holtzman D.M. J. Biol. Chem. 287:13959-13971(2012) · Mapped (25) |
| Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Jiang M., Wang J., Fu J., Du L., Jeong H., West T., Xiang L., Peng Q., Hou Z., Cai H. et al. Nat. Med. 18:153-158(2012) · Mapped (7) |
| Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. Kim J., Jiang H., Park S., Eltorai A.E., Stewart F.R., Yoon H., Basak J.M., Finn M.B., Holtzman D.M. J. Neurosci. 31:18007-18012(2011) · Mapped (18) |
| Dynamic analysis of amyloid beta-protein in behaving mice reveals opposing changes in ISF versus parenchymal Abeta during age-related plaque formation. Hong S., Quintero-Monzon O., Ostaszewski B.L., Podlisny D.R., Cavanaugh W.T., Yang T., Holtzman D.M., Cirrito J.R., Selkoe D.J. J. Neurosci. 31:15861-15869(2011) · Mapped (10) |
| In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. Yamada K., Cirrito J.R., Stewart F.R., Jiang H., Finn M.B., Holmes B.B., Binder L.I., Mandelkow E.M., Diamond M.I., Lee V.M. et al. J. Neurosci. 31:13110-13117(2011) · Mapped (9) |
| Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. Roe C.M., Fagan A.M., Grant E.A., Marcus D.S., Benzinger T.L., Mintun M.A., Holtzman D.M., Morris J.C. Arch. Neurol. 68:1145-1151(2011) · Mapped (16) |
| Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Cruchaga C., Nowotny P., Kauwe J.S., Ridge P.G., Mayo K., Bertelsen S., Hinrichs A., Fagan A.M., Holtzman D.M., Morris J.C. et al. Arch. Neurol. 68:1013-1019(2011) · Mapped (6) |
| Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Tarawneh R., D'Angelo G., Macy E., Xiong C., Carter D., Cairns N.J., Fagan A.M., Head D., Mintun M.A., Ladenson J.H. et al. Ann. Neurol. 70:274-285(2011) · Mapped (3) |
| Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., Patterson B.W., Fagan A.M., Morris J.C., Mawuenyega K.G., Cruchaga C. et al. Sci Transl Med 3:89ra57-89ra57(2011) · Mapped (13) |
| Critical role of astroglial apolipoprotein E and liver X receptor-alpha expression for microglial Abeta phagocytosis. Terwel D., Steffensen K.R., Verghese P.B., Kummer M.P., Gustafsson J.A., Holtzman D.M., Heneka M.T. J. Neurosci. 31:7049-7059(2011) · Mapped (2) |
| Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Fagan A.M., Shaw L.M., Xiong C., Vanderstichele H., Mintun M.A., Trojanowski J.Q., Coart E., Morris J.C., Holtzman D.M. Arch. Neurol. 68:1137-1144(2011) · Mapped (16) |
| Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., Lee J.M., Holtzman D.M. Nat. Neurosci. 14:750-756(2011) · Mapped (9) |
| Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. Kauwe J.S., Cruchaga C., Karch C.M., Sadler B., Lee M., Mayo K., Latu W., Su'a M., Fagan A.M., Holtzman D.M. et al. PLoS ONE 6:e15918-e15918(2011) · Mapped (41) |
| SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. Cruchaga C., Kauwe J.S., Mayo K., Spiegel N., Bertelsen S., Nowotny P., Shah A.R., Abraham R., Hollingworth P., Harold D. et al. PLoS Genet. 6:0-0(2010) · Mapped (7) |
| SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus. Satoh A., Brace C.S., Ben-Josef G., West T., Wozniak D.F., Holtzman D.M., Herzog E.D., Imai S. J. Neurosci. 30:10220-10232(2010) · Mapped (7) |
| Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. Kauwe J.S., Cruchaga C., Bertelsen S., Mayo K., Latu W., Nowotny P., Hinrichs A.L., Fagan A.M., Holtzman D.M., Goate A.M. J. Alzheimers Dis. 21:833-842(2010) · Mapped (7) |
| APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. Ann. Neurol. 67:122-131(2010) · Mapped (5) |